Cohen Capital Management buys $12,059,020 stake in Thermo Fisher Scientific (TMO)

Thermo Fisher Scientific (TMO) : Cohen Capital Management scooped up 650 additional shares in Thermo Fisher Scientific during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Oct 13, 2016. The investment management firm now holds a total of 79,320 shares of Thermo Fisher Scientific which is valued at $12,059,020.Thermo Fisher Scientific makes up approximately 3.62% of Cohen Capital Management’s portfolio.

Other Hedge Funds, Including , Marshwinds Advisory Co reduced its stake in TMO by selling 100 shares or 6.25% in the most recent quarter. The Hedge Fund company now holds 1,500 shares of TMO which is valued at $228,045. Thermo Fisher Scientific makes up approx 0.11% of Marshwinds Advisory Co’s portfolio.Genesee Valley Trust Co reduced its stake in TMO by selling 5 shares or 0.11% in the most recent quarter. The Hedge Fund company now holds 4,451 shares of TMO which is valued at $689,460. Thermo Fisher Scientific makes up approx 0.45% of Genesee Valley Trust Co’s portfolio.Bnp Paribas Arbitrage Sa reduced its stake in TMO by selling 14,412 shares or 40.93% in the most recent quarter. The Hedge Fund company now holds 20,803 shares of TMO which is valued at $3,292,699. Thermo Fisher Scientific makes up approx 0.01% of Bnp Paribas Arbitrage Sa’s portfolio. West Oak Capital added TMO to its portfolio by purchasing 29 company shares during the most recent quarter which is valued at $4,590.

Thermo Fisher Scientific closed down -4.21 points or -2.65% at $154.9 with 26,97,528 shares getting traded on Tuesday. Post opening the session at $156, the shares hit an intraday low of $153.79 and an intraday high of $156.585 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.

On the company’s financial health, Thermo Fisher Scientific reported $2.03 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $2.01. The company had revenue of $4535.20 million for the quarter, compared to analysts expectations of $4493.28 million. The company’s revenue was up 6.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.84 EPS.

Many Wall Street Analysts have commented on Thermo Fisher Scientific. JP Morgan Resumed Thermo Fisher Scientific on Sep 22, 2016 to “Overweight”, Price Target of the shares are set at $180.Thermo Fisher Scientific was Downgraded by Cleveland Research to ” Neutral” on Sep 9, 2016.

Thermo Fisher Scientific Inc. is a provider of analytical instruments equipment reagents and consumables software and services for research manufacturing analysis discovery and diagnostics. The company operates through four segments: Life Sciences Solutions provides reagents instruments and consumables used in biological and medical research discovery and production of new drugs and vaccines as well as diagnosis of disease; Analytical Instruments provides instruments consumables software and services that are used in the laboratory; Specialty Diagnostics offers diagnostic test kits reagents culture media instruments and associated products and Laboratory Products and Services offers self-manufactured and sourced products for the laboratory.

Leave a Reply

Thermo Fisher Scientific - Is it time to Sell?

Top Brokerage Firms are advising their investors on Thermo Fisher Scientific. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.